Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.79 USD
Change Today -0.21 / -3.00%
Volume 1.3K
SCYX On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 1:43 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

scynexis inc (SCYX) Snapshot

Open
$7.05
Previous Close
$7.00
Day High
$7.24
Day Low
$6.76
52 Week High
01/13/15 - $15.00
52 Week Low
10/16/14 - $5.70
Market Cap
94.4M
Average Volume 10 Days
19.4K
EPS TTM
$-2.09
Shares Outstanding
13.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SCYNEXIS INC (SCYX)

Related News

No related news articles were found.

scynexis inc (SCYX) Related Businessweek News

No Related Businessweek News Found

scynexis inc (SCYX) Details

SCYNEXIS, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, a novel oral drug that is in Phase II clinical trials; and an intravenous (IV) drug, which is conducting pre-clinical studies for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs that are approved for dry eye disease in humans and dogs. In addition, it provides contract research and development services in the field of animal health. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.

87 Employees
Last Reported Date: 03/30/15
Founded in 1999

scynexis inc (SCYX) Top Compensated Officers

Founder and Director
Total Annual Compensation: $533.2K
Compensation as of Fiscal Year 2014.

scynexis inc (SCYX) Key Developments

Scynexis, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

SCYNEXIS, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $64,000 compared to $65,000 a year ago. Loss from operations was $6,493,000 or compared to $4,013,000 a year ago. Loss from continuing operations was $6,492,000 compared to income from continuing operations $1,671,000 a year ago. Net loss attributable to common stockholders – diluted was $9,497,000 or $0.53 per diluted share compared to $5,326,000 or $1.08 per diluted share a year ago. Net loss per common share, diluted was $0.78 compared to $0.98 a year ago. Net loss was $9,497,000 against net income of $2,233,000 for the same period a year ago. The increase in the loss from operations of $2.5 million for 2015 compared to 2014 was due to an increase in research and development expenses and an increase in selling, general and administrative expenses of $1.0 million in the 2015 period primarily associated with continued public reporting company operating expenses, a non-recurring non-cash stock compensation charge, and accrued severance and other compensation costs. For the six months, the company reported total revenue of $129,000 compared to $130,000 a year ago. Loss from operations was $12,425,000 compared to $6,474,000 a year ago. Loss from continuing operations was $12,423,000 compared to income from continuing operations of $1,403,000 a year ago. Net loss attributable to common stockholders – diluted was $15,881,000 or $1.20 per diluted share compared to of $9,371,000 or $3.49 a year ago. Net loss per common share, diluted was $0.1.53 compared to $3.08 a year ago. Net loss was $15,881,000 against net income of $2,645,000 for the same period a year ago.

SCYNEXIS, Inc. announced delayed 10-Q filing

On 08/14/2015, SCYNEXIS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

SCYNEXIS, Inc. Appoints Jonathan Sears Woodall as Interim Chief Financial Officer

On July 22, 2015, Jonathan Sears Woodall joined SCYNEXIS, Inc. as its interim chief financial officer (CFO). Mr. Woodall will serve as SCYNEXIS’s principal financial and accounting officer and will report to Marco Taglietti, M.D., chief executive officer. Mr. Woodall brings to SCYNEXIS over 25 years experience of broad business, operational and corporate finance and reporting, risk management, taxation, treasury and public accounting experience.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCYX:US $6.79 USD -0.21

SCYX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCYX.
View Industry Companies
 

Industry Analysis

SCYX

Industry Average

Valuation SCYX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCYNEXIS INC, please visit www.scynexis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.